Journal
NATURE CLINICAL PRACTICE ONCOLOGY
Volume 4, Issue 5, Pages 305-315Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncponc0812
Keywords
Kaiso; MBD2; MBD4; MeCP2; methyl-binding domain
Categories
Funding
- Medical Research Council [G0301154] Funding Source: Medline
- MRC [G0301154] Funding Source: UKRI
- Medical Research Council [G0301154] Funding Source: researchfish
Ask authors/readers for more resources
The methyl-CpG-binding domain (MBD) proteins 'read' and interpret the methylation moieties on DNA, and thus are critical mediators of many epigenetic processes. Currently, the MBD family comprises five members; MBD1, MBD2, MBD3, MBD4 and MeCP2. Although not a 'classical' MBD protein, Kaiso also mediates transcriptional repression by using zinc finger domains to bind its targets. Since DNA hypermethylation is a well-recognized mechanism underlying gene silencing events in both tumorigenesis and drug resistance, it is likely that the MBD proteins may be important modulators of tumorigenesis. We review the recent work addressing this possibility, and discuss several of the MBD proteins as potentially excellent novel therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available